Timing and criteria for prophylactic thyroidectomy in asymptomatic RET carriers - The role of Ct serum level

Thyroid Research

Volumn 6, Issue SUPPL.1, 2013, Pages

  Jarzab, Barbara ^a   Szpak Ulczok, Sylwia ^a   Wloch, Jan ^a,b   Czarniecka, Agnieszka ^a   Krajewska, Jolanta ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84875330869     PISSN: None     EISSN: 17566614     Source Type: Journal    
DOI: 10.1186/1756-6614-6-S1-S9     Document Type: Review

References (14)

1. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P, Wells SA Jr, Hum Mol Genet 1993 2 7 851 6 10.1093/hmg/2.7.851 8103403 (Pubitemid 23216611)
2. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, gardner E, Love DR, Mole SE, Moore JK, Papi L, Ponder MA, Telenius H, Tunnacliffe A, Ponder BAJ, Nature 1993 363 6428 458 60 10.1038/363458a0 8099202 (Pubitemid 23179393)
3. Estimation of risk of inherited medullary thyroid carcinoma in apparent sporadic patients. Wiench M, Wygoda Z, Gubala E, Wloch J, Lisowska K, Krassowski J, Scieglinska D, Fiszer-Kierzkowska A, Lange D, Kula D, Zeman M, Roskosz J, Kukulska A, Krawczyk Z, Jarzab B, J Clin Oncol 2001 19 5 1374 80 11230481 (Pubitemid 32202543)
4. Multiple endocrine neoplasia type 2: achievements and current challenges. Machens A, Dralle H, Clinics 2012 67 S1 113 118 10.6061/clinics/2012(Sup01)19 22584715
5. Guidelines for diagnosis and therapy of MEN type 1 and type 2. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips CJ, Lombardi G, Mannelli M, Pacini F, Ponder BA, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells SA Jr, Marx SJ, J Clin Endocrinol Metab 2001 86 12 5658 71 10.1210/jc.86.12.5658 11739416 (Pubitemid 33152604)
6. Medullary thyroid cancer: management guidelines of the American Thyroid Association. American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, Evans B, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M, Wells SA Jr, Thyroid 2009 19 6 565 612 10.1089/thy.2008.0403 19469690
7. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, van Amstel HK, Lips CJ, Nishisho I, Takai SI, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjöld M, Komminoth P, Hendy GN, Mulligan LM, JAMA 1996 276 19 1575 9 10.1001/jama.1996.03540190047028 8918855 (Pubitemid 26384740)
8. The timing of total thyroidectomy in RET gene mutation carriers could be personalized and safely planned on the basis of serum Ct: 18 years experience at one single center. Elisei R, Romei C, Renzini G, Bottici V, Cosci B, Molinaro E, Agate L, Cappagli V, Miccoli P, Berti P, Faviana P, Ugolini C, Basolo F, Vitti P, Pinchera A, J Clin Endocrinol Metab 2012 97 2 426 35 10.1210/jc.2011-2046 22162466
9. Prophylactic thyroidectomy in RET carriers at risk for hereditary medullary thyroid cancer. Machens A, Dralle H, Thyroid 2009 19 6 551 4 10.1089/thy.2009.0144 19499987
10. Prognostic factors of disease-free survival after thyroidectomy in 170 young patients with a RET germline mutation: a multicenter study of the Groupe Francais d'Etude des Tumeurs Endocrines. Rohmer V, Vidal-Trecan G, Bourdelot A, Niccoli P, Murat A, Wemeau JL, Borson-Chazot F, Schvartz C, Tabarin A, Chabre O, Chabrier G, Caron P, Rodien P, Schlumberger M, Baudin E, Groupe Français des Tumeurs Endocrines, J Clin Endocrinol Metab 2011 96 3 509 18 10.1210/jc.2010-1234 21190982
11. Surgical treatment of hereditary medullary thyroid cancer and its modification, based on DNA diagnostics of germline RET mutations and investigation of tumor molecular profile [in Polish]. Wloch J, Nowotwory-Pol J Oncology 2007 57 suppl 5 1 51 2277780
12. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Giraudet A, Ghulzan A, Auperin A, Leboulleux S, Chehboun A, Troalen F, Dromain C, Lumbroso J, Baudin E, Schlumberger M, Eur J Endocrinol 2008 158 239 246 10.1530/EJE-07-0667 18230832 (Pubitemid 351298542)
13. Presentation of points of general discussion and voting among the speakers of the European Thyroid Association-Cancer Research Network (ETA-CRN) Meeting in Lisbon, 2009, entitled European Comments to ATA Medullary Thyroid Cancer Guidelines Jarzab B, Król A, Hasse-Lazar K, Jurecka-Lubieniecka B, Thyroid Research 2013 6 Suppl 1 11
14. Early malignant progression of hereditary medullary thyroid cancer. Machens A, Niccoli-Sire P, Hoegel J, Frank-Raue K, van Vroonhoven TJ, Roeher HD, Wahl RA, Lamesch P, Raue F, Conte-Devolx B, Dralle H, European Multiple Endocrine Neoplasia (EUROMEN) Study Group, N Engl J Med 2003 349 16 1517 25 10.1056/NEJMoa012915 14561794 (Pubitemid 37255037)